Simplification of testing and treatment in the quest to eliminate hepatitis C infection
Globally, 71 million people are living with hepatitis C virus (HCV) infection, but the burden of HCV continues to increase. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <20% to 90% and the number of eligible persons receiving HCV treatment from <10% to 80%. To achieve these targets, targeted interventions are needed to enhance HCV testing, linkage to care, and treatment (“the HCV care cascade”). This presentation reviews available evidence on strategies that have been successfully used to enhance HCV testing, linkage to care.
Early diagnosis of HIV and use of molecular Point-of-Care HIV testing as part of a comprehensive strategy to end HIV transmission
According to UNAIDS1 the world is embarking on a Fast-Track strategy to end the AIDS epidemic by 2030. There is a strong global consensus that powerful tools now exist to end the AIDS epidemic.
Bringing Molecular Testing Closer to the Patient
Our Educational Sites
Get the Right Test
The flu season is variable and its impact widespread. This challenge is compounded by the coinciding RSV and Strep A season. On Get The Right Test, you can learn how rapid molecular testing can reduce collection-to-result time, decrease number the of tests performed, and support antimicrobial stewardship. Stay in the know by signing up for weekly flu tracker updates during the flu season.
Diagnostics First
Each time a microorganism becomes resistant to an antibiotic, we lose another weapon in the war against infection. Fight back against antibiotic resistance with diagnostics first. Sign up today to receive customized, educational content and learn how on-demand molecular testing can help achieve your institution’s Infection Prevention and Antimicrobial Stewardship goals.
The GeneXpert® System: How Does it Help You Deliver Better Care?
Delivering better care begins with using the best technology. See how Cepheid’s GeneXpert cartridge technology is paving the way for more innovative medicine.
Xpert HCV VL Fingerstick - Near Patient Testing for Hepatitis C
The WHO has set a goal to eliminate Hepatitis C by 2030. England will strive for 2025.
HPV Testing in Cape Town – See How One Clinic is Making a difference for Women
There are many health challenges, particularly for women, in South Africa. Learn how a community-based clinic research project is making a difference.
The GeneXpert® System: How Does it Help You Deliver Better Care?
Delivering better care begins with using the best technology. See how Cepheid’s GeneXpert cartridge technology is paving the way for more innovative medicine.
Xpert HCV VL Fingerstick - Near Patient Testing for Hepatitis C
The WHO has set a goal to eliminate Hepatitis C by 2030. England will strive for 2025.
HPV Testing in Cape Town – See How One Clinic is Making a difference for Women
There are many health challenges, particularly for women, in South Africa. Learn how a community-based clinic research project is making a difference.
1. https://www.ncbi.nlm.nih.gov/pubmed/22491338 Hall, AJ., et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012
2. ModernMedicine Network. Chronic Myeloid Leukemia. Accessed Nov 27 2018. http://www.cancernetwork.com/chronic-myeloid-leukemia/chronic-myeloid-leukemia
3. Woessner, David W et al. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 2011;17(6):477-86. https://www.ncbi.nlm.nih.gov/pubmed/22157291
4. Goldberg S et al. Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. Clin Lymph, Myel & Leuk. 2017; 18(2):98-105. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30991-6/fulltext